Publikationen | Institut für Hämatopathologie Hamburg

Adenosquamous Carcinoma of the Pancreas Comprise a Heterogeneous Group of Tumors With the Worst Outcome: A Clinicopathological Analysis of 25 Cases Identified in 562 Pancreatic Carcinomas Resected With Curative Intent

Adenosquamöses Karzinom des Pankreas, Adenosquamous carcinoma of the pancreas, ASCAP, K5/14, p63

Boecker W et al. Adenosquamous Carcinoma of the Pancreas Comprise a Heterogeneous Group of Tumors With the Worst Outcome: A Clinicopathological Analysis of 25 Cases Identified in 562 Pancreatic Carcinomas Resected With Curative Intent. Pancreas 2020; May/Jun 2020;49(5):683-691. doi: 10.1097/MPA.0000000000001548

Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC

Anti-angiogenic, vascular endothelial growth factor (VEGF)

Volz C et al. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. Cell Rep 2020; Apr 28;31(4):107568. doi: 10.1016/j.celrep.2020.107568

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease

Angioimmunoblastic T-cell lymphoma, Angioimmunoblastisches T-Zell-Lymphom, Hodgkin lymphoma, HodgkinLymphom, Ligand PD-L1, Receptor PD-1, Rezeptor PD-1

Tiemann M et al. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease. BMC Res Notes 2020; Mar 7;13(1):139. DOI: 10.1186/s13104-020-04975-w

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC

EGFR, NSCLC, TKI, TP53

Roeper J et al. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC. Oncotarget 2020; Jan 21;11(3):250-264. doi: 10.18632/oncotarget.27430

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

ALK, ALK Translokation, anaplastic lymphoma kinase (ALK) rearrangement, fluorescence in situ hybridisation (FISH), Fluoreszenz in situ Hybridisierung (FISH), Immunhistochemie, immunohistochemistry, non small cell lung cancer (NSCLC)

Thunnissen E et al. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer 2019; Dec;138:13-18. doi: 10.1016/j.lungcan.2019.09.023

Mast cell chymase: morphofunctional characteristics

Chymase, Mast cells, Mastzelle

Atiakshin D et al. Mast cell chymase: morphofunctional characteristics. Histochem Cell Biol 2019; Oct;152(4):253-269. DOI: 10.1007/s00418-019-01803-6

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

Lung cancer, NSCLC, ROS1, Targeted treatment, TP53, zielgerichtete Therapie

Michels S et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol 2019; Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020.